Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01695239 · ClinicalTrials.gov registry record · Phase 3
A Study of Ixekizumab in Participants With Active Psoriatic Arthritis
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 417
- Enrollment target
NCT01695239 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 417 participants.
The verdict
NCT01695239, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 417 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active psoriatic arthritis.
Interventions
- DRUG Placebo
- DRUG Adalimumab
- DRUG Ixekizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 417 participants |
| Start Date | 2012-12 |
| Est. Completion | 2017-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01695239
The ClinicalTrials.gov registry entry for NCT01695239 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 417 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01695239 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01695239 about?
NCT01695239 is a clinical study titled "A Study of Ixekizumab in Participants With Active Psoriatic Arthritis". This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to placebo in participants with active psoriatic arthritis.
What is the current status of trial NCT01695239?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 417 participants. The study started on 2012-12. Estimated completion is 2017-09.
What interventions are being tested in trial NCT01695239?
The interventions under investigation include: Placebo (DRUG), Adalimumab (DRUG), Ixekizumab (DRUG).
Who is sponsoring clinical trial NCT01695239?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.